India to Mexico: Rituximab Export Trade Route

The India to Mexico Rituximab corridor is one of India's established pharmaceutical export routes, with 37 shipments documented worth a combined $719.8K USD. The route is dominated by HETERO BIOPHARMA LIMITED, which alone accounts for roughly 83% of all export value, reflecting the consolidated nature of India's rituximab manufacturing sector.

Across 11 active suppliers, the average shipment value stands at $19.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 71% of all shipments, consistent with rituximab's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 33.1%, placing it at rank #9 among India's top rituximab export destinations globally.

On the import side, key buyers of Indian rituximab in Mexico include XXAROXXPHAXXA SXX DXXC V, TO THE ORDER OF,, TOTAL SHIPPING SA DE CV , and 9 others. XXAROXXPHAXXA SXX DXXC V is the single largest importer with 2 shipments valued at $597.2K USD.

India's rituximab exports to Mexico are driven primarily by a handful of large-scale manufacturers. HETERO BIOPHARMA LIMITED with 2 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 11 active exporters signals a competitive but concentrated market — buyers in Mexico benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — HETERO BIOPHARMA LIMITED, MEDINEX HEALTHCARE, MYGENIC HEALTHCARE PRIVATE LIMITED — together account for 95% of total trade value on this route. The average shipment value of $19.5K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as rituximab(maball)100mg/10ml vial1x2s m and maball 500 mg inj (rituximab), suggesting that buyers in Mexico tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, XXAROXXPHAXXA SXX DXXC V is the largest importer with 2 shipments worth $597.2K USD — representing 83% of all rituximab imports from India on this route. A total of 12 buyers are active on this corridor.